[go: up one dir, main page]

PE20240933A1 - Profarmaco de derivados de pirrolidona como activador de glucocinasa - Google Patents

Profarmaco de derivados de pirrolidona como activador de glucocinasa

Info

Publication number
PE20240933A1
PE20240933A1 PE2024000460A PE2024000460A PE20240933A1 PE 20240933 A1 PE20240933 A1 PE 20240933A1 PE 2024000460 A PE2024000460 A PE 2024000460A PE 2024000460 A PE2024000460 A PE 2024000460A PE 20240933 A1 PE20240933 A1 PE 20240933A1
Authority
PE
Peru
Prior art keywords
alkenyl
alkyl
compound
formula
prodrug
Prior art date
Application number
PE2024000460A
Other languages
English (en)
Inventor
Fuxing Tang
Jin She
Li Chen
Guanghua Lv
Xiangle Jin
Original Assignee
Hua Medicine Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd
Publication of PE20240933A1 publication Critical patent/PE20240933A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invencion proporciona un compuesto de formula (I), o un producto isotopicamente marcado, un enantiomero, un diastereoisomero o una sal farmaceuticamente aceptable del mismo; una composicion farmaceutica que comprende un compuesto de formula (I); y el uso de un compuesto de formula (I) o una composicion farmaceutica del mismo en el tratamiento de la diabetes mellitus y sintomas relacionados. En particular, se refiere a un compuesto de formula (I), o un producto isotopicamente marcado, un enantiomero, un diastereoisomero o una sal farmaceuticamente aceptable del mismo: en donde indica un centro quiral, R1 es H, -C(O)R6, -C(O)OR6, entre otros; R2 es -C(O)R3, -C(O)OR3, -C(O)NR4R5, entre otros; o R1 y R2 se conectan para formar -CHRd-, -SiRdRe-, -C(O)-, entre otros; R3 es H, alquilo de C1-6, alquenilo de C2-6, entre otros; R4 y R5 es H, alquilo de C1-6, alquenilo de C2-6, entre otros; R6 es H, alquilo de C1-6, alquenilo de C2-6, entre otros; Rd y Re se seleccionan independientemente de H, alquilo de C1-6, alquenilo de C2-6, entre otros.
PE2024000460A 2021-09-15 2022-09-15 Profarmaco de derivados de pirrolidona como activador de glucocinasa PE20240933A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111079620 2021-09-15
CN202211093895 2022-09-08
PCT/CN2022/118947 WO2023040937A1 (en) 2021-09-15 2022-09-15 Prodrug of pyrrolidone derivatives as glucokinase activator

Publications (1)

Publication Number Publication Date
PE20240933A1 true PE20240933A1 (es) 2024-04-30

Family

ID=83505858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000460A PE20240933A1 (es) 2021-09-15 2022-09-15 Profarmaco de derivados de pirrolidona como activador de glucocinasa

Country Status (18)

Country Link
US (2) US12054477B2 (es)
EP (1) EP4244221B1 (es)
JP (1) JP7751731B2 (es)
KR (1) KR20240044465A (es)
CN (1) CN117940419A (es)
AR (1) AR127064A1 (es)
AU (1) AU2022346020A1 (es)
CA (1) CA3231566A1 (es)
CL (1) CL2024000738A1 (es)
CO (1) CO2024002748A2 (es)
EC (1) ECSP24020925A (es)
GE (1) GEAP202416483A (es)
IL (1) IL311237A (es)
MX (1) MX2024003068A (es)
PE (1) PE20240933A1 (es)
TW (1) TW202328107A (es)
WO (1) WO2023040937A1 (es)
ZA (1) ZA202402086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020451966A1 (en) * 2020-06-04 2023-01-19 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa
WO2024251159A1 (zh) 2023-06-06 2024-12-12 华领医药技术（上海）有限公司 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂
US20250195440A1 (en) 2023-12-14 2025-06-19 Hua Medicine USA Inc. Pharmaceutical formulation comprising glucokinase activator and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
EP2276479B1 (en) 2008-04-15 2014-07-02 SineVir Therapeutics LLC Prodrugs of neuraminidase inhibitors
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772541B2 (en) 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
BR112015015229B1 (pt) 2012-12-25 2020-07-07 Hua Medicine processo para a preparação de um composto da fórmula, e, composto
EP3317273B1 (en) 2015-06-30 2021-12-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
PL3556354T3 (pl) 2016-12-15 2025-11-03 Hua Medicine (Shanghai) Ltd. Doustny preparat aktywatora glukokinazy i sposób jego wytwarzania
KR20200011426A (ko) 2017-04-20 2020-02-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-ras 조절인자
CN110548147B (zh) * 2018-05-31 2022-01-14 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和dpp-iv抑制剂的药物组合及其制备方法和用途
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
US10689360B1 (en) 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11008303B2 (en) 2019-01-30 2021-05-18 Insilico Medicine Ip Limited TLR 9 inhibitors
WO2022040604A1 (en) 2020-08-21 2022-02-24 BioAge Labs, Inc. Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients

Also Published As

Publication number Publication date
KR20240044465A (ko) 2024-04-04
IL311237A (en) 2024-05-01
TW202328107A (zh) 2023-07-16
GEAP202416483A (en) 2024-04-25
WO2023040937A1 (en) 2023-03-23
JP7751731B2 (ja) 2025-10-08
EP4244221A1 (en) 2023-09-20
US20240336597A1 (en) 2024-10-10
AR127064A1 (es) 2023-12-13
CO2024002748A2 (es) 2024-03-27
CA3231566A1 (en) 2023-03-23
CN117940419A (zh) 2024-04-26
US20230322738A1 (en) 2023-10-12
EP4244221B1 (en) 2025-12-10
CL2024000738A1 (es) 2024-08-30
ZA202402086B (en) 2024-11-27
US12054477B2 (en) 2024-08-06
JP2024533536A (ja) 2024-09-12
ECSP24020925A (es) 2024-04-30
AU2022346020A1 (en) 2024-03-21
MX2024003068A (es) 2024-03-27

Similar Documents

Publication Publication Date Title
PE20240933A1 (es) Profarmaco de derivados de pirrolidona como activador de glucocinasa
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
RU2008107733A (ru) Ингибиторы gsk-3
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
DOP2009000201A (es) Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc
UY27666A1 (es) Nuevos derivados de piridina y quinolina
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
AR066881A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
ECSP099706A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
CL2009001554A1 (es) Compuestos derivados de 4-(sulfonilaminoalquilamino)-n-fenil-n'-hidroxi-1,2,5-oxadiazol-3-carboximidamida; formas cristalinas; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades tales como cancer, infeccion viral, depresion, entre otras.
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
AR039063A1 (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion, medicamento, un proceso para su preparacion, utilizacion de dichos derivados para la preparacion de un medicamento
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
PE20060680A1 (es) Compuestos de morfolina sustituida como inhibidores de la recaptacion de norepinefrina
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
AR045113A1 (es) Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
AR073844A1 (es) Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
DOP2006000243A (es) Derivados de pirazina
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR074454A1 (es) Compuestos 4-(-heterocicloalquil) benceno-1,3-diol como inhibidores de la tirosinasa, y su uso en medicina humana y tambien en cosmetica